KEI Comments Regarding NIH Proposed License T Cell Cancer Therapy to Moonlight Bio

On October 12, 2023, Knowledge Ecology International (KEI) filed comments regarding the “Prospective Grant of an Exclusive Patent License: Development and Commercialization of Engineered T Cell Therapies for the Treatment of Cancer” by the National Institutes of Health (NIH) to… Continue Reading

Summary of KEI’s September 28, 2023 comments to the TRIPS Council On Paragraph 8 Of The Ministerial Decision On The TRIPS Agreement

Summary of September 28, 2023 comments to the TRIPS Council On Paragraph 8 Of The Ministerial Decision On The TRIPS Agreement James Love Knowledge Ecology International (KEI) The June 17, 2022 decision on the TRIPS Agreement and COVID-19 vaccines was… Continue Reading

Save the Date – 17 October 2023 – US Government FAR 52.227-1 authorization for non-voluntary use of patents (in-person only)

Knowledge Ecology International (KEI) invites WIPO delegates attending the 35th session of the Standing Committee on the Law of Patents (SCP) to a side event on Tuesday, 17 October 2023. James Love’s slides can be found here: https://www.keionline.org/wp-content/uploads/52.227-1-wipo-17oct2023.pdf Title: US… Continue Reading

Scarlet TCR: Comments on a NIH prospective exclusive patent license for treatment of HPV cancers

Updates: Senator Sanders Sends Letter to HHS Inspector General Urging Investigation of Exclusive Patent License for NIH-funded Cancer Therapy, Press Release. October 23, 2023. David Dayen, “Sanders Seeks Investigation of NIH Licensing Practices: The senator wants the inspector general to… Continue Reading

KEI Comments to CMS Regarding Imbruvica (INN:Ibrutinib) R&D (regarding Medicare pricing negotiations)

On October 2, 2023, Knowledge Ecology International submitted written comments to the Centers for Medicare & Medicaid Services (CMS) in conjunction with the Medicare Price Negotiation public consultation process. CMS is hosting a series of patient-focused listening sessions this fall,… Continue Reading

Letter to FDA on the Cost to the Public of the Pediatric Trial Exclusivity Extension

Today, Knowledge Ecology International (KEI) submitted a letter to the Commissioner of the Food and Drug Administration (FDA) regarding the mismatch between the cost to perform pediatric extension trials and the cost to the public of the six month extension… Continue Reading

Delinkage embedded in the three UN Political Declarations on PPPR, tuberculosis, and universal health coverage

On 1 September 2023, Csaba Kőrösi, President of the 77th United Nations General Assembly, circulated three draft texts of political declarations related to the following processes: High-level meeting on pandemic prevention, preparedness and response(resolution77/275) High-level meeting on universal health coverage… Continue Reading